Ratings Arecor Therapeutics plc

Equities

Delayed London S.E. Other stock markets 12:20:50 13/06/2024 BST			5-day change	1st Jan Change
130 ^GBX	+1.96%		-18.24%	-28.77%

06-10	Political turmoil hits euro and banks	AN
06-10	Europe heads lower amid political turmoil in EU	AN

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

	1st Jan change	Capi.	ESG Refinitiv
ARECOR THERAPEUTICS PLC	-28.77%	50.14M	-
MODERNA, INC.	+48.54%	56.61B	B-
IQVIA HOLDINGS INC.	-6.02%	39.62B	B
LONZA GROUP AG	+37.12%	39.25B	A
CELLTRION, INC.	-6.90%	28.28B	C
ICON PUBLIC LIMITED COMPANY	+12.97%	26.44B	B-
ALNYLAM PHARMACEUTICALS, INC.	-16.91%	20.12B	B
UNITED THERAPEUTICS CORPORATION	+28.18%	12.51B	B+
MEDPACE HOLDINGS, INC.	+31.71%	12.48B	C+
BIO-TECHNE CORPORATION	+0.38%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality